Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study.

Hum Psychopharmacol

Department of Psychiatry, Comenius University, Bratislava, Slovakia.

Published: August 2002

In a 6-week, multicentre, randomised, double-blind controlled study, tianeptine (37.5 mg/day) and fluoxetine (20 mg/day) were compared for efficacy and safety in 178 patients with major depression. No significant difference was shown between the two drugs, either in terms of efficacy (MADRS, CGI, COVI) or in terms of safety, except for the CGI 'severity of illness' which was lower at the end point with tianeptine than with fluoxetine. The percentages of responders (as defined by a 50% decrease of the MADRS score from baseline to end point) were 75% with tianeptine and 67% with fluoxetine, showing the efficacy of both drugs. In conclusion, both tianeptine and fluoxetine are effective and well-tolerated treatments for major depression.

Download full-text PDF

Source
http://dx.doi.org/10.1002/hup.411DOI Listing

Publication Analysis

Top Keywords

tianeptine fluoxetine
12
major depression
12
randomised double-blind
8
tianeptine
5
fluoxetine major
4
depression 6-week
4
6-week randomised
4
double-blind study
4
study 6-week
4
6-week multicentre
4

Similar Publications

Background: The objective is to compare the risk of developing type 2 diabetes (T2D) within a year in patients prescribed various antidepressants (ADs) and those prescribed fluoxetine as a control group.

Methods: This study used standardized data from the Health Insurance Review and Assessment Service claims database (n=1,456,489). Patients aged ≥10 years with no previous use of ADs and no history of diabetes mellitus, regardless of whether they were diagnosed with any depressive disorder, were eligible for this study.

View Article and Find Full Text PDF

: Several psychological conditions, including stress and depression, can adversely affect oral health; in fact, antidepressants, commonly used to treat depressive disorders, may have conflicting effects on the periodontal status of individuals. The aim of this review was to determine the effects of antidepressants on the periodontium. A literature search was conducted using electronic databases, Pubmed/MEDLINE, Cochrane Library, focusing on the use of antidepressants and their effects on periodontal health in animals or humans.

View Article and Find Full Text PDF

Risk Assessment of Psychotropic Drugs on Mitochondrial Function Using In Vitro Assays.

Biomedicines

December 2023

Department of Pharmaceutical Sciences, Barry & Judy Silverman College of Pharmacy, Nova Southeastern University, 3200 South University Drive, Ft. Lauderdale, FL 33328-2018, USA.

Article Synopsis
  • This study explores how 22 psychotropic drugs affect mitochondrial function, specifically looking at their potential to cause organ toxicity.
  • Several drugs were found to inhibit the electron transport chain (ETC) or act as uncouplers, with varying levels of cytotoxicity identified in HepG2 cells and isolated rat liver mitochondria.
  • The findings help clarify the molecular mechanisms behind drug-induced mitochondrial toxicity, which can inform safer clinical drug choices.
View Article and Find Full Text PDF

Proregenerative and neuroprotective effects of antidepressants are an important topic of inquiry in neuropsychiatric research. Oxygen-glucose deprivation (OGD) mimics key aspects of ischemic injury in vitro. Here, we studied the effects of 24-h pretreatment with serotonin (5-HT), citalopram (CIT), fluoxetine (FLU), and tianeptine (TIA) on primary mouse cortical neurons subjected to transient OGD.

View Article and Find Full Text PDF

An update on potential pharmacotherapies for cognitive impairment in bipolar disorder.

Expert Opin Pharmacother

April 2023

Mood Disorders Psychopharmacology Unit (MDPU), Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

Introduction: Cognitive impairment is a core feature of bipolar disorder (BD) that impedes recovery by preventing the return to optimal socio-occupational functioning and reducing quality of life. Presently, there are no efficacious treatments for cognitive impairment in BD, but many pharmacological interventions are being considered as they have the potential to target the underlying pathophysiology of the disorder.

Areas Covered: This review summarizes the available evidence for pharmacological interventions for cognitive impairment in bipolar disorder.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!